We are live on ! Find out more

Biohaven

BHVN

Market cap $1.96B

12.97 USD

+0.10

0.78%

At close Updated Oct 5, 4:00 PM EDT

Pre-market

After hours

12.97

0.00

0%

1 day

0.78%

5 days

-1.14%

1 month

-11.89%

3 months

-19.19%

6 months

41.75%

Year to date

19.65%

1 year

-18.32%

5 years

81.65%

10 years

81.65%

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Employees: 274

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 30%

Neutral 45%

Negative 25%

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development. First-in-class FGFR3 ADC: BHV-1530 is a first-in-class potential FGFR3-directed antibody-drug conjugate incorporating Biohaven's proprietary TopoIx payload, that has shown early clinical activity with a differentiated and tolerable safety profile.

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Biohaven Ltd (NYSE: BHVN) dropped $2.21, or about 14.73%, on September 10, 2026 after the Company disclosed that the FDA placed a partial clinical hold on new-patient enrollment in the Company's BHV-7000/opakalim epilepsy trials.

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.

Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

Biohaven Ltd. (NYSE:BHVN) on Thursday announced a partial clinical hold issued by the U.S. Food and Drug Administration (FDA) on new patient enrollment for its BHV-7000 program, while maintaining timelines for its lead pivotal study in refractory focal epilepsy.

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

Investors Business Daily

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent findings, sending its ‌shares down more than 13% in premarket trading.

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

The Motley Fool

Why Biohaven Stock Was Rocking the Market This Week

Its partner is South Korean peer SK Biopharmaceuticals. It also secured a victory in a lawsuit.

Why Biohaven Stock Was Rocking the Market This Week

Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More

Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform with SK Biopharmaceuticals. BHVN-1300's phase 3 for Graves' disease is underway; BHV-1400's phase 3 for IgA nephropathy is set to start in H2 2026. Opakalim [BHV-7000] for refractory focal epilepsy is fully enrolled in phase 2/3, with topline data expected in H2 2026 and a $350M upfront SK Biopharmaceuticals deal secured.

Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

Biohaven secures a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, notably opakalim. This agreement immediately strengthens BHVN's cash position, reduces R&D costs, and extends the funding runway, addressing prior liquidity concerns. I am upgrading BHVN to Buy, citing promising degrader pipeline assets targeting large autoimmune markets and pivotal trial initiations.

Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

Zacks Investment Research

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

See News Rankings

Price charts implemented using Lightweight Charts™